BNTX vs. ARGX, BIIB, NBIX, RGEN, QGEN, EXEL, PCVX, RVMD, MRNA, and GILD
Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include argenx (ARGX), Biogen (BIIB), Neurocrine Biosciences (NBIX), Repligen (RGEN), Qiagen (QGEN), Exelixis (EXEL), Vaxcyte (PCVX), Revolution Medicines (RVMD), Moderna (MRNA), and Gilead Sciences (GILD). These companies are all part of the "biological products, except diagnostic" industry.
argenx (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.
argenx has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
BioNTech has a net margin of 24.26% compared to BioNTech's net margin of -23.26%. argenx's return on equity of 4.60% beat BioNTech's return on equity.
argenx received 485 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.75% of users gave argenx an outperform vote while only 42.26% of users gave BioNTech an outperform vote.
In the previous week, BioNTech had 3 more articles in the media than argenx. MarketBeat recorded 11 mentions for BioNTech and 8 mentions for argenx. BioNTech's average media sentiment score of 0.83 beat argenx's score of 0.54 indicating that argenx is being referred to more favorably in the media.
60.3% of argenx shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.4% of argenx shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
argenx currently has a consensus price target of $528.16, suggesting a potential upside of 41.67%. BioNTech has a consensus price target of $120.40, suggesting a potential upside of 38.06%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts plainly believe argenx is more favorable than BioNTech.
Summary
argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.
Get BioNTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNTech Competitors List
Related Companies and Tools
